DRUG

$72.13

Post-MarketAs of Mar 17, 8:00 PM UTC

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$72.13
Potential Upside
5%
Whystock Fair Value$75.74
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epile...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$705.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-26.98%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
56.59

Recent News

TipRanks
Mar 6, 2026

Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, FDA alignment and a DSMB recommendation. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential HELUS PHARMA REPORTS PHASE 2 HLP004 RESULTS: Helus Pharma (HELP) announced Thursday topline results from a Phase

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Feb 19, 2026

Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials

Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the most promising stocks. TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares. The update […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 26, 2025

Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why

Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 25, 2025

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Oct 15, 2025

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable

Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.